NCT06298448

eGPA and Local Inflammation Within the Ear, Nose and Throat Area

Impact of Mepolizumab Treatment on the Nasal Microbiome and Local and Systemic Immune Response in Eosinophilic Granulomatosis With Polyangitis (eGPA)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 150 (estimated)
• Sponsor: University Medical Center Groningen · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Rationale: Eosinophilic Granulomatosis with Polyangiitis (eGPA), eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are airway diseases where eosinophils and interleukine-5 are involved in the pathogenesis. eGPA differs from the other diseases with respect to involvement of other organs. The investigators hypothesize that nasal microbiome dysbiosis with a central augmenting role for S. Aureus plays an important role in disease expression. The investigators expect that anti-interleukin-5 treatment with mepolizumab restores the changes of the nasal microbiome and immune responses to a healthy control phenotype. To study this, the nasal microbiome, the local and systemic immune response and the effect of mepolizumab treatment will be assessed.

Detailed description

See Brief summary.

Conditions

• EGPA - Eosinophilic Granulomatosis With Polyangiitis

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	laboratory experiments before and after mepolizumab treatment	Patients that start with mepolizumab treatment on the basis of the clinical disease course will be measured prior and after start of mepolizumab to evaluate the effects this medication has on various immunological parameters and microbiome

Timeline

• Start date: 2024-02-14
• Primary completion: 2027-12-01
• Completion: 2028-12-01
• First posted: 2024-03-07
• Last updated: 2024-03-07

Locations

1 site across 1 country: Netherlands